Leap In Molecular Diagnostics Attributed To AI System

Seegene, a developer of multiplex PCR technologies, using a unique artificial intelligence ("AI") based assay development system, has developed molecular diagnostics ("MDx") assays in four (4) days. The assays are high multiplex real-time PCR reagents developed in their entirety by AI and are designed to simultaneously detect eight different DNA targets for each of meningitis and sexually transmitted infections.

 

The company confirms the performance (sensitivity and specificity) of the assays developed by AI are equivalent to or even better than that of those manually developed and only four (4) days were sufficient to successfully develop two 8-plex assays, while more than a year was required by a team of experienced professionals.

Sponsored by Digi-Key

Industrial Ethernet Solutions from ADI Chronous™ Available Now from Digi-Key

ADI’s Chronous portfolio of edge-to-enterprise Industrial Ethernet connectivity solutions is designed to accelerate your path to Industry 4.0. The compatible and interoperable Industrial connectivity products enable best-in-class performance.

 

The AI-based automated assay development system, called the "Seegene Digitalized Development System (SG-DDS)", automates real-time PCR assay development utilizing big data of causative agents for diseases, Seegene's novel algorithms, and in silico oligonucleotide design with virtual experiments. This advancement significantly reduces the time and labor required for R&D and simplifies complicated real time PCR assay development processes, allowing non-professionals to easily develop multiplex MDx assays of their desire.

 

With SG-DDS, Project 100 will be completed to significantly increase the number of CE marked Allplex assays within this year. The pipeline includes assays that diagnose not only infectious diseases but also drug resistant, genetic disorders and various cancers including lung, breast and colon cancers.

 

Seegene's current business focus is the human IVD market, but the company is also preparing to pioneer non-human IVD areas as well. For its future assay portfolio, Seegene has included food safety, agriculture, aquaculture, animal health and other non-human related diagnostic assays to expand its already vast offerings. Further, Seegene plans to develop customized assays that can meet varied needs. More scintillating info is available, acquirable by visiting Seegene.

Read more on

Suggested Articles

DFKI’s Andreas Dengel sees a next stage for AI that makes it more practical for business applications

COVID-19 has influenced LCD pricing, but Chinese government subsidies are expected to help future Chinese players

Chipmaker Intel focuses on virus help as well as new tech to protect against future crises